We note pyruvate therapy, which serves to regenerate NAD+, was recently shown to decrease serum GDF15, a circulating marker of the ISR, in mitochondrial disease patients (Koga et al., 2019), providing rich in vivo support for our identification of NADH imbalance as a trigger of the ISR. This evidence concerns the gene GDF15 and inborn mitochondrial metabolism disorder.